Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

BUY
$36.54 - $54.26 $1.46 Million - $2.17 Million
40,000 New
40,000 $1.49 Million
Q3 2022

Nov 09, 2022

BUY
$59.5 - $86.7 $1.11 Million - $1.62 Million
18,672 New
18,672 $1.3 Million

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Toronto Dominion Bank Portfolio

Follow Toronto Dominion Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

News

Stay updated on Toronto Dominion Bank with notifications on news.